BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9713500)

  • 1. Comparison of effects of surfactants with other MDR reversing agents on intracellular uptake of epirubicin in Caco-2 cell line.
    Lo YL; Hsu CY; Huang JD
    Anticancer Res; 1998; 18(4C):3005-9. PubMed ID: 9713500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.
    Lo YL
    J Control Release; 2003 Jun; 90(1):37-48. PubMed ID: 12767705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
    Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
    Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
    Lo YL; Liu FI; Yang JM; Cherng JY
    Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin.
    Lo YL; Ho CT; Tsai FL
    Eur J Pharm Sci; 2008 Sep; 35(1-2):52-67. PubMed ID: 18606222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
    Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
    BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium deoxycholate and sodium caprate on the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats.
    Lo YL; Huang JD
    Biochem Pharmacol; 2000 Mar; 59(6):665-72. PubMed ID: 10677583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing effect of N-octyl-O-sulfate chitosan on etoposide absorption.
    Mo R; Xiao Y; Sun M; Zhang C; Ping Q
    Int J Pharm; 2011 May; 409(1-2):38-45. PubMed ID: 21356302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
    Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
    FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
    Chen F; Wang T; Wang J; Wang ZQ; Qian M
    Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
    Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
    Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport.
    Hilgendorf C; Spahn-Langguth H; Rhedin M; Regårdh CG; Löwenadler B; Langguth P
    Mol Pharm; 2005; 2(1):64-73. PubMed ID: 15804179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines.
    Lo Y; Liu F; Cherng J
    J Control Release; 2001 Sep; 76(1-2):1-10. PubMed ID: 11532308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
    Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
    J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.
    Weinheimer M; Fricker G; Burhenne J; Mylius P; Schubert R
    Eur J Pharm Sci; 2017 Oct; 108():13-22. PubMed ID: 27590127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.